SuperworthVivoSim Labs, INC. price to sales ratio VIVS
Market value divided by revenue over the last twelve months, since 2025.
- Today, Oct 23, 2026
- 19.7×
- Peer median
- 1.0×
VivoSim Labs, INC.'s price to sales ratio is 19.7× as of Oct 23, 2026.
The median for 8 healthcare stocks of a similar size is 1.0×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 19.7× | 9.2× | 54.4× |
| 2025 | 37.4× | 20.5× | 76.7× |
Against its peers
Companies in Healthcare nearest VivoSim Labs, INC.'s size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| VIVSVivoSim Labs, INC. | 19.7× |
| OXBROXBRIDGE RE HOLDINGS | 2.8× |
| EDUCEducational Development | 0.4× |
| GTIMGood Times Restaurants | 0.1× |
| MDRRMedalist Diversified | 1.6× |
| BCGBinah Capital | 0.1× |
| VIPVulcan Infrastructure & Power | 0.4× |
| MXCMexco Energy | 3.0× |
| CKXCKX Lands | 31.0× |
| Peer median | 1.0× |
Where VivoSim Labs, INC. ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on VivoSim Labs, INC.
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.